Matthew J. Petzold

Voltari Operating Corp. is engaged in the provision of mobile data solutions serving mobile operators, consumer brands and enterprises, and advertising agencies. The company was founded on March 17, 2004 and is headquartered in New York, NY.

Verestar, Inc. is a company that owns and operates wireless communications towers. The company is based in Fairfax, VA. Verestar was acquired by SES AMERICOM, Inc. on December 01, 2004 for $18.50 million.

UUNET Technologies, Inc. is the world's largest provider of Internet services, offering a comprehensive range of access options, World Wide Web hosting services, security products and consulting services to businesses, professionals, and on-line service providers. The company's network is comprised of Points of Presence (POPs) throughout the United States and in Canada, Europe and the Asia-Pacific region, as well as connections to Internet service providers around the world. Founded in 1987, UUNET is recognized as the first commercial Internet service provider

Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL.

Sprout Pharmaceuticals, Inc. provides delivery of a treatment option for the unmet need of women with Hypoactive Sexual Desire Disorder. The company was founded by Cynthia E. Whitehead and Robert S. Whitehead on November 29, 2011 and is headquartered in Raleigh, NC.

KeifeRx LLC is a clinical-stage biopharmaceutical company that develops novel and optimized tyrosine kinase inhibitors (TKIs) for the treatment of neurodegenerative and immune diseases. KeifeRx is based in McLean, VA, and was founded in 2019 by Charbel Moussa and Fernando Pagan. The company's clinical pipeline is led by Nilotinib BE, an optimized, lower dose formulation of Nilotinib, which is currently in a multicenter phase 3 clinical trial for early Alzheimer's disease. KeifeRx's TKI portfolio includes an optimized oral dose of Bosutinib and Gutinib, which are undergoing clinical trials in Lewy body dementia and optimizing and IND enabling studies, respectively. The company's technologies are designed to treat neurodegenerative diseases and an array of inflammatory diseases where there are significant unmet clinical needs and limited therapeutic options. Chris Hoyt has been the CEO of the company since 2021.